Collaboration with Novartis

Aduro Biotech Inc.

Our attorneys represented Aduro Biotech, Inc. in the negotiation of a major collaboration with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products.  Under the terms of the agreement, Novartis has paid $200 million to Aduro and, if development milestones are met, Aduro is eligible to receive up to an additional aggregate amount of $500 million.

Email Disclaimer